A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Clinical trial NCT05933070 · TERMINATED
Trial details
- NCT number
- NCT05933070
- Sponsor
- Inmune Bio, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-15
- Primary completion
- 2024-03-28
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.